The human microbiome market is expected to reach USD 1,930.25 million by 2030, driven by technological advancements and rising health awareness. The market’s compound annual growth rate (CAGR) is forecasted to be around 15.7%.
This growth can be attributed to the increasing understanding of the microbiome’s role in health and disease. The human microbiome has been found to play a crucial role in various health conditions, including obesity, autoimmune disorders, antibiotic resistance, genomic disorders, gastrointestinal diseases, cancer, Crohn’s syndrome, and irritable bowel syndrome.
The market is segmented based on application into therapeutics and diagnostics. Therapeutics dominated the market share in 2023 and is expected to maintain its dominance due to rising awareness of microbiome-based therapies. The diagnostics segment is also growing rapidly, driven by advancements in microbiome sequencing technologies and increasing adoption of microbiome testing for disease diagnosis.
The human microbiome market is characterized by the presence of several key players, including Metabiomics Corporation, Yakult Honsha Co., Ltd., Microbiome Therapeutics, LLC, Seres Therapeutics Inc., and DuPont. Collaborative efforts between industry players, academic institutions, and research organizations are driving innovation in microbiome-based solutions.
The market is expected to witness significant growth in regions such as the United States, Germany, China, Japan, and India. These countries have robust healthcare infrastructure, advanced technologies, and a growing awareness of gut health, contributing to the market’s growth.
Source: https://industrytoday.co.uk/market-research-industry-today/human-microbiome-market-rapid-growth-driven-by-technological-advancements-and-rising-health-awareness